Clinical value of costly ER/PR testing of ductal carcinoma biopsies questioned
Limiting hormone receptor testing of diagnostic core biopisies containing ductal carcinoma in situ (DCIS) could save up to $35 million in associated health care costs every year in the United...
Source: Ob.Gyn. News - Category: OBGYN Source Type: research
More News: Cancer & Oncology | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Health | Health Management | Hormones | OBGYN